PAX6 is required for proper development of the eye, central nervous system,
and nose. PAX6 has two DNA binding domains, a glycine-rich region that lin
ks the two DNA binding domains, and a transactivation domain. There is evid
ence that the different DNA binding domains of PAX6 have different target g
enes. However, it is not clear if the two DNA binding domains function inde
pendently. We have studied the effect of structural changes in the paired d
omain on the function of PAX6 mediated through its homeodomain, The R26G an
d I87R mutations have been reported in different human patients with clinic
ally different phenotypes and are in the N- and the C-terminal halves of th
e paired domain, respectively. Surprisingly, we found that the I87R mutant
protein not only lost the transactivation function but also failed to bind
DNA by either of its DNA binding domains. In contrast, the R26G mutant prot
ein lost DNA binding through its paired domain but had greater DNA binding
and transactivation than wild-type PAX6 on homeodomain binding sites. Like
R26G, the 5a isoform showed higher DNA binding than wild-type PAX6, This st
udy demonstrates that the two subdomains of the paired domain influence the
function of the homeodomain differentially and also provides an explanatio
n for the difference in phenotypes associated with these mutations.